Young streak off a low base: a short run of consecutive-period improvement has just started, after a stretch that gave i
The model's full reasoning — Q4 2022 call → NOWe need answer YES or NO based on transcript. Need determine if management conveys a young run of consecutive improvements in a part of business that previously unimpressive, causes company-specific and still in force. Let's analyze transcript. Need answer only YES or NO. We must evaluate three conditions. Management discusses several parts. Which part? Could be Libtayo? EYLEA? Dupixent? Maybe "Libtayo" had steady growth? But Libtayo has been performing? They mention "In lung cancer, Libtayo continues to see steady growth in utilization in prescribers. Customer ordering has accelerated following the chemotherapy combination approval last November. We are working to maximize launch uptake by increasing depth and breath of prescribers. Early launch indicators are positive..." That's one period? Not necessarily young run from unimpressive stretch. Also they mention "Outside U.S., Libtayo net sales grew 60% on constant currency basis to $59 million driven by steady demand growth and additional launches..." Not sequential. What about EYLEA? "fourth quarter U.S. net sales of $1.5 billion, full year 2022 net sales were $6.3 billion, representing 8% year-over-year growth and outpacing total growth of anti-VEGF category for the year. At the end of fourth quarter, EYLEA category share was approaching previous levels of approximately 50% of injections. This followed the short-term shift earlier in the quarter where EYLEA was negatively impacted by a temporary increase in use of off-label compounded Avastin. During this time, there was a short-term closure of a not-for-profit patient co-pay assistance fund, which reopened later in the quarter. We believe we have substantially recovered from the issue encountered in the fourth quarter." This suggests recovery from a temporary issue, not a young run of improvement? It says "approaching previous levels" after short-term shift. Not consecutive periods. What about Dupixent? It has been growing strongly, long-established. "2022 turned out to be phenomenal year... growing 44%..." Not unimpressive before. What about aflibercept 8mg? Not launched yet. Potential part: "Regeneron Genetics Medicine" or "oncology pipeline" no.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| ASB | Associated Banc-Corp | Q1 2024 | 2024-04-25 | A |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| OLPX | Olaplex Holdings, Inc. | Q4 2023 | 2024-02-29 | D |
| MNKD | MannKind Corporation | Q4 2023 | 2024-02-27 | C |
| GPRE | Green Plains Inc. | Q4 2023 | 2024-02-07 | F |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| BMBL | Bumble Inc. | Q3 2023 | 2023-11-07 | F |
| ALL | The Allstate Corporation | Q3 2023 | 2023-11-02 | C+ |
| GOLD | Barrick Gold Corporation | Q3 2023 | 2023-11-02 | C |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| TEL | TE Connectivity Ltd. | Q4 2023 | 2023-11-01 | B |
| SBRA | Sabra Health Care REIT, Inc. | Q1 2023 | 2023-05-04 | B |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| PKOH | Park-Ohio Holdings Corp. | Q3 2022 | 2022-11-13 | B |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| LEG | Leggett & Platt, Incorporated | Q3 2021 | 2021-11-02 | C |
| UFI | Unifi, Inc. | Q4 2021 | 2021-08-07 | B |
| ESRT | Empire State Realty Trust, Inc. | Q2 2021 | 2021-07-29 | C+ |
| LRN | Stride, Inc. | Q1 2019 | 2018-10-23 | B |
| ORAN | Orange SA | Q2 2018 | 2018-07-26 | B |
| AVT | Avnet, Inc. | Q2 2018 | 2018-01-25 | B |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| SPR | Spirit AeroSystems Holdings, Inc. | Q1 2016 | 2016-04-29 | D |
WRBY · Q1 2024 → YESThe question is about whether management conveys a short, still-young run of consecutive periods of real improvement in a part of the business that was previously unimpressive, caused by company-speci...
ASB · Q1 2024 → YESThe question is about whether management conveys a short, still-young run of consecutive periods of real improvement in a part of the business that was previously unimpressive, caused by company-speci...
KOPN · Q4 2023 → YESThe question is about whether management conveys a short, still-young run of consecutive periods of real improvement in a part of the business that was previously unimpressive, caused by company-speci...